INTRODUCTION
1. Papp KA, et al. N Engl J Med 2017; 376: 1551-60. 
OBJECTIVE
• The objective of this analysis was to examine the distribution of PASI responses in patients from the phase 2 trial treated with risankizumab versus ustekinumab.
MATERIALS & METHODS

RESULTS
CONCLUSIONS
• The overall improvements in PASI scores at weeks 12 and 16 were higher in patients treated with 90 or 180 mg risankizumab compared with ustekinumab.
• Patients treated with 90 or 180 mg risankizumab showed a greater shift in PASI distribution towards PASI 90-100 response rates compared with ustekinumab-treated patients.
• Risankizumab is a humanized IgG1 monoclonal antibody that inhibits IL-23 by binding its p19 subunit. In a phase 2 trial, risankizumab demonstrated superiority over ustekinumab in patients with moderate to severe plaque psoriasis. 1
• Response rates derived from dichotomizing a continuous variable at a certain threshold (eg, 90% improvement in Psoriasis Area and Severity Index, PASI 90) are often used as primary endpoints in clinical trials to demonstrate efficacy of investigational products.
• However, additional visualization of the cumulative distribution of responses can help assess the consistency of PASI improvement at the population level.
STUDY DESIGN AND PATIENTS
• Patients (N=166) with moderate to severe plaque psoriasis were randomized to receive subcutaneous injections of risankizumab (18 mg single dose, 90 or 180 mg at weeks 0, 4, and 16) or ustekinumab (45 or 90 mg, based on body weight at weeks 0, 4, and 16, Figure 1 ). 
Figure 1. Study Design of Phase 2 Trial of Risankizumab in Psoriasis Patients
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• The proportions of patients achieving different levels of PASI responses were assessed at weeks 12 and 16 in an intent-to-treat population.
• Patients with a missing assessment were counted as non-responders for that assessment.
• Cumulative probability plots were generated to assess the distribution of changes from baseline in PASI score across treatment groups.
• The proportions of patients achieving PASI 75, PASI 90, and PASI 100 responses are shown in Figure 2 .
• At week 12, the proportions of patients achieving the primary end point of PASI 90 response were 30.2% (13/43), 73.2% (30/41), and 78.6% (33/42) for 18 mg, 90 mg, and 180 mg risankizumab groups, respectively, compared with 40% (16/40) for ustekinumab-treated patients (Figure 2) . 1
Figure 2. PASI 75, PASI 90, and PASI 100 Response Rates Through Week 16 (NRI)
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Week 4 Week 8 Week 12 Week 16 • Patients treated with 90 mg or 180 mg of risankizumab achieved higher response rates across all levels of PASI improvement when compared with patients treated with 18 mg risankizumab (single dose) or ustekinumab (Figure 3) .
Figure 3. Distribution of Changes in PASI Responses from Baseline at Weeks 12 and 16 (NRI)
Week 12 Week 16 12 and 16 (NRI) • The cumulative probability plot demonstrated that patients treated with 90 or 180 mg of risankizumab had a higher likelihood of achieving greater improvements from baseline in PASI score compared with patients treated with 18 mg risankizumab or ustekinumab (Figure 4) .
-Median values for improvement in PASI scores at week 12 were 81.7%, 94.6%, and 98.8% in patients treated with 18 mg, 90 mg, and 180 mg of risankizumab, respectively, compared with 85.6% in ustekinumab-treated patients. -At week 16, median values for improvement in PASI scores were 87.4%, 97.5%, and 100.0% in patients treated with 18 mg, 90 mg, and 180 mg of risankizumab, respectively, compared with 87.0% in ustekinumab-treated patients. (NCT02054481), contributed to its design and participated in data collection. AbbVie participated in data analysis and interpretation of the data, and in writing, review, and approval of the publication. Medical writing support was provided by Deepa Venkitaramani, PhD, of AbbVie. a. One patient each with missing response in risankizumab 18 mg and ustekinumab 45/90 mg groups, and were imputed as having no (0%) improvement. Abbreviations: NRI=non-responder imputation; PASI=Psoriasis Area and Severity Index.
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